Petagine Lucy, Zariwala Mohammed Gulrez, Patel Vinood B
Center for Nutraceuticals, School of Life Sciences, University of Westminster, London W1W 6UW, United Kingdom.
World J Biol Chem. 2021 Sep 27;12(5):87-103. doi: 10.4331/wjbc.v12.i5.87.
Alcoholic liver disease (ALD) due to chronic alcohol consumption is a significant global disease burden and a leading cause of mortality. Alcohol abuse induces a myriad of aberrant changes in hepatocytes at both the cellular and molecular level. Although the disease spectrum of ALD is widely recognized, the precise triggers for disease progression are still to be fully elucidated. Oxidative stress, mitochondrial dysfunction, gut dysbiosis and altered immune system response plays an important role in disease pathogenesis, triggering the activation of inflammatory pathways and apoptosis. Despite many recent clinical studies treatment options for ALD are limited, especially at the alcoholic hepatitis stage. We have therefore reviewed some of the key pathways involved in the pathogenesis of ALD and highlighted current trials for treating patients.
长期饮酒所致的酒精性肝病(ALD)是一项重大的全球疾病负担,也是主要的死亡原因。酒精滥用在细胞和分子水平上都会导致肝细胞发生无数异常变化。尽管ALD的疾病谱已广为人知,但疾病进展的确切触发因素仍有待充分阐明。氧化应激、线粒体功能障碍、肠道菌群失调和免疫系统反应改变在疾病发病机制中起重要作用,触发炎症途径的激活和细胞凋亡。尽管最近有许多临床研究,但ALD的治疗选择仍然有限,尤其是在酒精性肝炎阶段。因此,我们回顾了一些参与ALD发病机制的关键途径,并重点介绍了目前治疗患者的试验。